102 related articles for article (PubMed ID: 21573668)
41. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Mellish KJ; Kelland LR
Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
[TBL] [Abstract][Full Text] [Related]
43. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
44. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
[TBL] [Abstract][Full Text] [Related]
45. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR
Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
[TBL] [Abstract][Full Text] [Related]
46. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
[TBL] [Abstract][Full Text] [Related]
47. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
[TBL] [Abstract][Full Text] [Related]
48. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
Raynaud FI; Odell DE; Kelland LR
Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, characterization and anti-tumour testing of some platinum(II) amine complexes containing 1,1- and 1,2-cyclobutanedicarboxylate ligands.
Hill WE; McAuliffe CA; Sharma HL; Zaki A
Chem Biol Interact; 1990; 73(2-3):337-51. PubMed ID: 2155716
[TBL] [Abstract][Full Text] [Related]
51. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).
Chaney S
Int J Oncol; 1995 Jun; 6(6):1291-305. PubMed ID: 21556672
[TBL] [Abstract][Full Text] [Related]
52. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
53. Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991.
McKeage MJ; Higgins JD; Kelland LR
Br J Cancer; 1991 Oct; 64(4):788-92. PubMed ID: 1911229
[TBL] [Abstract][Full Text] [Related]
54. Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants.
Perego P; Zunino F; Carenini N; Giuliani F; Spinelli S; Howell SB
Mol Pharmacol; 1998 Jul; 54(1):213-9. PubMed ID: 9658208
[TBL] [Abstract][Full Text] [Related]
55. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
56. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
Brooks SE; Korbut TT; Dupuis NP; Holden SA; Teicher BA
Cancer Chemother Pharmacol; 1995; 36(5):431-8. PubMed ID: 7634385
[TBL] [Abstract][Full Text] [Related]
57. Synthesis, antiproliferative activity and DNA binding study of mixed ammine/cyclohexylamine platinum(II) complexes with 1-(substituted benzyl) azetidine-3, 3-dicarboxylates.
Sun Y; Gou S; Yin R; Jiang P
Eur J Med Chem; 2011 Oct; 46(10):5146-53. PubMed ID: 21875765
[TBL] [Abstract][Full Text] [Related]
58. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.
Farrell N; Kelland LR; Roberts JD; Van Beusichem M
Cancer Res; 1992 Sep; 52(18):5065-72. PubMed ID: 1516063
[TBL] [Abstract][Full Text] [Related]
59. In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma.
Barbara C; Orlandi P; Bocci G; Fioravanti A; Di Paolo A; Natale G; Del Tacca M; Danesi R
Eur J Pharmacol; 2006 Nov; 549(1-3):27-34. PubMed ID: 16978599
[TBL] [Abstract][Full Text] [Related]
60. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]